Azafaros Switzerland AG
Azafaros is a clinical-stage company, led by a team of highly experienced industry experts, which aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to rare disease patients and their families. Azafaros is supported by a syndicate of leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Date, time and room information
Monday, May 4, 15:15 – 15:30, room Montreal
Category
Clinical stage development company
Title of the presentation
Nizubaglustat: Redefining Treatment for Neurological Lysosomal Diseases
Speaker information
| Name | Position | Institution |
|---|---|---|
| Stefano Portolano | CEO |
